Kane Biotech

Kane Biotech EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Kane Biotech (KNE.V) as of Oct 21, 2026 is -95.30 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -157.60 % — a change of -39.53% (higher).

EBIT/Assets

-95.30 %

YoY

-39.53%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Kane Biotech is 2025 -95.30 % . Operating Income to Assets Ratio (EBIT/Assets) of Kane Biotech was 2024 -157.60 % . It decreases by -39.53% higher compared to the previous year.

The Kane Biotech EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-204.43 CAD
Jan 1, 2019
-126.32 CAD
Jan 1, 2020
-83.89 CAD
Jan 1, 2021
-79.61 CAD
Jan 1, 2022
-55.20 CAD
Jan 1, 2023
-67.30 CAD
Jan 1, 2024
-157.60 CAD
Jan 1, 2025
-95.30 CAD
The Kane Biotech EBIT/Assets history
YEAREBIT/AssetsYoY
-95.30 %-39.53%
-157.60 %+134.18%
-67.30 %+21.92%
-55.20 %-30.66%
-79.61 %-5.10%
-83.89 %-33.59%
-126.32 %-38.21%
-204.43 %+156.14%
-79.81 %-33.64%
-120.28 %-12.49%
-137.44 %+79.54%
-76.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kane Biotech stock

Operating Income to Assets Ratio (EBIT/Assets) of Kane Biotech is -95.30 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Kane Biotech changed from -157.60 % to -95.30 %, representing a -39.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Kane Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Kane Biotech

All Key Metrics — Kane Biotech